Athens, Greece - A dose-response study of the ACE-inhibitor enalapril (Vasotec® - Merck) in congestive heart failure (CHF) patients found no difference in survival and clinical status in patients ...

Please provide your email address to receive an email when new articles are posted on . Enalapril was not superior to standard care for preventing chemotherapy-related cardiotoxicity for breast cancer ...

Sacubitril/valsartan shows evidence of benefit in the first randomized trial evaluating a drug treatment for patients with ...